Nicox presented positive Phase 3 clinical data for NCX 470, a nitric oxide-donating bimatoprost formulation, at the American Glaucoma Society's 2026 annual congress. The investigational eye drop demonstrated intraocular pressure (IOP) reductions of up to 10 millimeters of mercury, meeting the company's primary efficacy thresholds required for regulatory submissions in the United States and China.
The trial results showed NCX 470 achieved statistically significant IOP-lowering superiority over latanoprost, a first-line glaucoma treatment, at three of six measurement timepoints evaluated during the study period. The compound maintained a favorable tolerability profile, with low discontinuation rates attributed to adverse events, supporting its potential as a therapeutic option for patients with glaucoma or ocular hypertension.
These data represent a key milestone for Nicox's clinical development program, positioning the company to advance regulatory discussions with health authorities regarding approval pathways in major markets. The combination of superior efficacy at select timepoints and robust safety profile strengthens NCX 470's competitive positioning within the glaucoma treatment landscape.